Cellular Bi (CBMG)

NASDAQ
19.75
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    19.74/19.80
  • Day's Range:
    19.73 - 19.75

CBMG Overview

Prev. Close
19.75
Day's Range
19.73-19.75
Revenue
30K
Open
19.74
52 wk Range
12.95-19.75
EPS
-2.83
Volume
0
Market Cap
384.69M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
55,267
P/E Ratio
-
Beta
1.19
1-Year Change
7.16%
Shares Outstanding
19,478,048
Next Earnings Date
-
What is your sentiment on Cellular Bi?
or
Market is currently closed. Voting is open during market hours.

Cellular Bi News

  • Cellular Biomedicine reports FY results
    • BySeeking Alpha-

    Cellular Biomedicine (NASDAQ:CBMG): FY EPS of -$1.78Revenue of $0.34M (-46.0% Y/Y)Press ReleaseNow read: Portola: Elucidating The Latest Developments On BevyxxaOriginal article

  • Premarket analyst action - healthcare
    • BySeeking Alpha-

    Perrigo (NASDAQ:PRGO), Supernus Pharmaceuticals (NASDAQ:SUPN) and Flexion Therapeutics (NASDAQ:FLXN) initiated with Buy ratings at Berenberg.Cellular Biomedicine (NASDAQ:CBMG)...

  • Midday Gainers / Losers
    • BySeeking Alpha-

    Gainers: MYSZ +70%. DELT +29%. APHB +22%. GALT +18%. SIFY +17%. AMSC +17%. LPCN +17%. VUZI +17%. NVRO +16%. CBMG +16%. Losers: AXON -51%. PLAY -20%. GPRO -20%. MFGP -17%. ALQA...

Cellular Bi Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

Cellular Bi Company Profile

Cellular Bi Company Profile

Employees
217

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York. As of February 19, 2021, Cellular Biomedicine Group, Inc. was taken private.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.